

CANNAPHARMAR_X

HIGH-QUALITY CRAFT AND MEDICAL CANNABIS



OUR MISSION

CannapharmaRx is a cannabis services company committed to producing high quality medical and recreational cannabis operated through our state of the art facility in Cremona, AB, Canada, with an annual capacity of over 6,000 Kg of high grade flower.

Our short and long term strategy is to deliver against the demands of international cannabis markets by providing the best quality products and to help companies either build their own brands or supply new markets with superior cannabis products under our wholly owned brand, Formosa.

200 MILLION

Cannabis users
worldwide

CANNAPHARMARx

Over 700
desirable strains



THE CANNAPHARMARX APPROACH TO ESG

The CannaPharmaRx investor has needs and preferences that can be defined in terms of risk tolerance, return objectives, time horizon, and liquidity. Many also have needs and preferences that relate to Environmental, Social and Governance issues.

CannaPharmaRx understands that its' Investor motivations related to ESG vary greatly but are important guiding principles as to how we operate day to day and approach today's ever evolving market. Some of the core motivations for our team stem from a desire to:

- **Incorporate Ethical Principles, Values, Or Aboriginal Traditions Into Our Daily Processes;**
- **Avoid ESG Risks That May Negatively Affect The Perception Of CannaPharmaRx;**
- **Contribute, Wholly Or Partially, To The Attainment Of Specific, Positive, Measurable Environmental Or Social Outcomes.**

As a result, a wide variety of corporate policies are considered to fulfill on our ESG mandate. CannaPharmaRx Inc. will continue to strive to be better today than we were yesterday as it relates specifically to our ESG standards.






GLOBAL CANNABIS MARKET FROM 2023 TO 2028

(in billions USD)

2023	27.7
2024	34.7
2025	43.5
2026	54.5
2027	68.3
2028	85.5



Source:
www.grandviewresearch.com/industry-analysis/legal-cannabis-market

TOP CHALLENGES FOR LOCAL CANNABIS COMPANIES

Complexities in creating a brand and establishing a local presence in new markets



Low quality
genetics



Product quality
issues



Increased
production costs



Downward
pricing pressures



Increased
competition




Oversupply



High
Marketing costs



Consumer
Loyalty




Online
Technology



Fragmented
Industry



Regulatory
Challenges



COMPANY TARGETS

CannaPharmaRx's ability to set itself apart from its competitors stems from its strong knowledge and experience of our growers and over 700 unique, high-quality genetic strains we own. The diverse array of cultivars support market demands for Sativa, Indica and hybrids, each with their own unique features.

Our primary goal is to supply highly sought after cultivars to international markets supporting the continuous demand for consistent, quality products.

CannaPharmaRx is in relentless pursuit of acquisitions to support the evolution of the cannabis space whether it is products, packaging or services that will provide cutting-edge technology for online marketing, e-commerce, and advanced inventory management that will support our market partners in their local countries to increase sales and dominate the burgeoning online cannabis market.




OUR UNIQUE SOLUTION

✓ **Unique Brands**

Our partners can chose different products to supply their own brands, or from our brand portfolio.

✓ **Flexibility in Quantity**

Our customers can manage their orders, changing the quantity according to their needs



✓ **Inventory Management**

The flexible model allows our customers to sell their oversupply products to other customers within our ecosystem

✓ **Savings in Operational Costs**

Our customers will benefit from a significant cost reduction and decreased workforce necessary to maintain an independent cannabis farm

✓ **Technology Support**

CannaPharmaRx has developed online technology and tools for marketing, retention, and inventory management that will help our customers with their online strategy

INDOOR CULTIVATION FACILITY

The company operates a high-end indoor cannabis facility in Cremona, Alberta, Canada. The facility is equipped to produce 6,000 kg of high-quality cannabis per year.

- Indoor Purpose-Built Facility
- 55,000 Square Foot
- Low-Consumption Solar Panels
- 10 Growing Rooms
- 10 Drying And Packing Rooms
- Health Canada License
- EU-GMP License (In Progress)
- Israel IMC-GAP Certification – Achieved December 2023



WORLD LEADERS IN UNIQUE GENETIC STRAINS

5-year production plan



High-Quality Cannabis
10 Unique Brands



Medical Cannabis
1:1 THC – CBD strains



Craft Products
High THC and rich with terpenes



CBD Oil
CBD and THC Tinctures

BUSINESS STRATEGY MODEL

The company will focus its international sales strategy on the production and sales of high gross margin products, resulting in greater profitability using our sophisticated, state of the art facility in Cremona, Alberta.

Our target is to reach 60% gross margin on production of our craft style cannabis

- Growing Cannabis On Demand Against Purchase Contracts
- Smart Inventory Management
- Maintain High Gross Margin Levels Through Negotiated Supply Contracts
- Collaborate With International Partners
- Development Of Online, Data-Driven Technology



FAST GROWTH AND POSITIVE CASH FLOW

Advanced financial proformas illustrate that by controlling production and labour costs, CannapharmRx can reinvest profits to support rapid expansion and future acquisitions.

1 ROOM / YEAR	
Production	600 Kg
Revenue / 1 Kg	\$3,000/KG
TOTAL REVENUE	1,800,000 C\$

Labor Cost	246,000
Growth Cost	187,000
Allowance for Royalties	390,000
GROSS MARGINS	977,000 C\$ (54.2%)



BUSINESS FORECAST

The company plans to raise capital of \$2 million during 2024, which will be used to achieve its forecasted business plan.

Projected Revenue 2028



Annual Revenue
60M C\$



Europe | Israel

- **Timeline** - 18 months
- **Market** - Europe, Israel

Kilograms 6,000



Canada | USA

- **Timeline** - 60 months
- **Market** - North America

Kilograms 22,000


MEET OUR TEAM

The CannaPharmaRx Executive team is highly experienced in the cannabis market, with a proven track record to support scalable growth and each member has held various senior management positions in both publicly listed and private companies.

Both our corporate leaders and employees have extensive experience and knowledge in the cannabis industry as well as online technologies necessary for developing and growing a successful international cannabis business.



DEAN MEDWID
CEO



RICK ORMAN
Chairman of the Board



OLIVER FOESTE
CFO



ANTHONY PANEK
Director



ADAM MINDLE
Director





DOMINIC COLVIN
Director



COMPANY ACHIEVEMENTS



Company customers (2024 Forecast)

 Y.S.H Cannabis Company	<ul style="list-style-type: none">• 1 Brand• 10 Strains• 600 Kg / Year*
 Cantek	<ul style="list-style-type: none">• 3 Brands• 30 Strains• 1,800 Kg / Year*

*Export to Israel will start in March 2024
*Y.S.H holdings received exclusivity for marketing their brand in Israel

DISCLAIMER

The material contained in this presentation is intended as general background information on CannaPharmaRx and its activities. The information is supplied in summary form, and is therefore not necessarily complete. Also, it is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending on their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. The financial information contained in this presentation includes non-GAAP financial measures. The presentation includes statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions and results of operations and financial condition, including, without limitation, indicative revenue contribution by portfolio, expected medium term revenue growth and forecasted economic indicators and performance metric outcomes. These statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions. We use words such as 'may', 'expect', 'indicative', 'intend', 'forecast', 'estimate', 'anticipate', 'believe', or words with similar meanings to identify forward-looking statements. Should one or more of the risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from the expectations described in this presentation. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events.

All pictures shown are for illustration purposes only. Actual products may vary due to product enhancement.

CANNAPHARMAR_x

THANK YOU!

888 3RD STREET SW
CALGARY, AB T2P 5C5
CANADA

